Šalis: Izraelis
kalba: anglų
Šaltinis: Ministry of Health
ATROPINE SULFATE
RAZ PHARMACEUTICS LTD, ISRAEL
A03BA01
SOLUTION FOR INJECTION
ATROPINE SULFATE 1 MG / 1 ML
I.M, I.V
Required
S.A.L.F. S.P.A. LABORATORIO FARMACOLOGICO, ITALY
ATROPINE
Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension.Antidote in poisoning by organophosphorus.
2022-08-31
. טסוגוא 2019 ,ה/דבכנ ה/אפור /חקור ,ה/דבכנ ת :רישכתה לש אפורל ןולעה יכ םכעידוהל תשקבמ תוחקור זר תרבח ATROPINE SULPHATE S.A.L.F 1MG/ML .ןכדוע .אפורל ןולעב םייתוהמ םייוניש ושענ םהב םיפיעסה קר םיניוצמ וז העדוהב תופסותה םודא עבצב ונמוס ו ה תוקיחמ עבצב ונמוס םודא םע .הקיחמ וק :תואירבה דרשמ רתאבש תופורתה רגאמב ומוסרפ ךרוצל תואירבה דרשמל חלשנ ןכדועמה ןולעה www.health.gov.il :םושירה לעבל היינפ ידי לע ספדומ ולבקל ןתינו תוחקור זר ,מ"עב תכתמה בוחר 6 .ת.א , .המידק ,הכרבב ןומימ לאירא הנוממ תחקור ATROPINE SULPHATE S.A.L.F 1MG/ML :קזוחו ליעפ ביכרמ Atropine Sulphate 1 mg/ml :תרשואמ היוותה Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension . Antidote in poisoning by organophosphorus . :אפורל ןולעב ועצובש םינוכדעה 4.2 POSOLOGY AND METHOD OF ADMINISTRATION PRE-ANESTHETIC MEDICATION _Adults_: The recommended dose is 0.3-0.6 mg by intravenous injection immediately before the anesthesia induction or by intramuscular injection 30-60 minutes before the induction. _Children_: The recommended dose is 0.02 mg/kg (maximum dose 0.6 mg). TREATMENT OF SINUS BRADYCARDIA The recommended dose is between 0.3 and 1.0 mg intravenously. ANTIDOTE in poisoning by organophosphorus _Adults_: The recommended dose is 2 mg (intramuscularly or intravenously, taking into account the severity of the poisoning severity) every 5-10 minutes, until the skin becomes red and dry, the pupils dilate and tachycardia appears. _Children_: The recommended dose is 0.02 mg/kg. 4.3 CONTRAINDICATIONS Hypersensitivity to the active ingredient or to any of the excipients listed i Perskaitykite visą dokumentą
ATROPINE SULPHATE S.A.L.F 1 MG/ML 1. NAME OF THE DRUG Atropine Sulphate S.A.L.F 1mg/ml. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains: Active ingredient: Atropine Sulphate monohydrate 1 mg. For the full list of the excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. 4. CLINICAL INFORMATION 4.1 THERAPEUTIC INDICATIONS Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION PRE-ANESTHETIC MEDICATION _Adults_: The recommended dose is 0.3-0.6 mg by intravenous injection immediately before the anesthesia induction or by intramuscular injection 30-60 minutes before the induction. _Children_: The recommended dose is 0.02 mg/kg (maximum dose 0.6 mg). TREATMENT OF SINUS BRADYCARDIA The recommended dose is between 0.3 and 1.0 mg intravenously. ANTIDOTE in poisoning by organophosphorus _Adults_: The recommended dose is 2 mg (intramuscularly or intravenously, taking into account the poisoning severity) every 5-10 minutes, until the skin becomes red and dry, pupils dilate and tachycardia appears. _Children_: The recommended dose is 0.02 mg/kg. 4.3 CONTRAINDICATIONS Hypersensitivity to the active ingredient or to any of the excipients listed in section 6.1. Angle-closure glaucoma, esophageal reflux, pyloric stenosis, gastrointestinal obstruction, ulcerative colitis, prostatic hypertrophy, paralytic ileus, intestinal atony, myasthenia gravis (unless co-administered with anticholinesterase). However, all these contraindications are irrelevant in potentially fatal emergency situations (such as bradyarrhythmia, poisoning). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE The solution should be clear, colorless and free of visible particles. The ampoule is intended for a single, uninterrupted administration and any unused residual solution should be discarded. Atropine sulfate should be u Perskaitykite visą dokumentą